• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

C3 肾小球病。肾小球疾病的新视角。

C3 glomerulopathies. A new perspective on glomerular diseases.

机构信息

Servicio de Nefrología. Hospital Universitario 12 de Octubre. Madrid, Spain.

出版信息

Nefrologia. 2013;33(2):164-70. doi: 10.3265/Nefrologia.pre2012.Nov.11802.

DOI:10.3265/Nefrologia.pre2012.Nov.11802
PMID:23511752
Abstract

Membranoproliferative glomerulonephritis denotes a general pattern of glomerular injury that is easily recognised by light microscopy. With additional studies, MPGN subgrouping is possible. For example, electron microscopy resolves differences in electron-dense deposition location, while immunofluorescence typically detects the composition of electron-dense deposits. A C3 glomerulopathy (C3G) is a recently described entity, a proliferative glomerulonephritis (usually but not always), with a MPGN pattern on light microscopy, with C3 staining alone on immunofluorescence, implicating hyperactivity of the alternative complement pathway. The evaluation of C3G in a patient should focus on the complement cascade, as deregulation of the alternative pathway and terminal complement cascade underlies pathogenesis. Although there are no specific treatments currently available for C3G, a better understanding of their pathogenesis would set the stage for the possible use of anti-complement drugs, as eculizumab. In this review, we summarise the pathogenesis of the C3 glomerulopathies, focusing on the role of complement, the patient cohorts recently reported and options of treatment up to the current moment.

摘要

膜增生性肾小球肾炎表示一种易于通过光镜识别的肾小球损伤的一般模式。通过进一步研究,可能对 MPGN 进行亚组分类。例如,电子显微镜解析电子致密沉积物位置的差异,而免疫荧光通常检测电子致密沉积物的组成。C3 肾小球病 (C3G) 是一种新描述的实体,是一种增生性肾小球肾炎(通常但不总是),在光镜下呈 MPGN 模式,免疫荧光仅显示 C3 染色,提示补体旁路的过度活跃。在患者中评估 C3G 应侧重于补体级联,因为旁路和末端补体级联的失调是发病机制的基础。尽管目前尚无针对 C3G 的特定治疗方法,但更好地了解其发病机制将为可能使用补体药物(如依库珠单抗)奠定基础。在这篇综述中,我们总结了 C3 肾小球病的发病机制,重点介绍了补体的作用、最近报告的患者队列以及目前的治疗选择。

相似文献

1
C3 glomerulopathies. A new perspective on glomerular diseases.C3 肾小球病。肾小球疾病的新视角。
Nefrologia. 2013;33(2):164-70. doi: 10.3265/Nefrologia.pre2012.Nov.11802.
2
Membranoproliferative glomerulonephritis and C3 glomerulopathy: resolving the confusion.膜增生性肾小球肾炎和 C3 肾小球病:消除混淆。
Kidney Int. 2012 Mar;81(5):434-41. doi: 10.1038/ki.2011.399. Epub 2011 Dec 7.
3
Histopathology of MPGN and C3 glomerulopathies.MPGN 和 C3 肾小球病的组织病理学。
Nat Rev Nephrol. 2015 Jan;11(1):14-22. doi: 10.1038/nrneph.2014.217. Epub 2014 Dec 2.
4
Pathogenesis of the C3 glomerulopathies and reclassification of MPGN.C3 肾小球病的发病机制和 MPGN 的重新分类。
Nat Rev Nephrol. 2012 Nov;8(11):634-42. doi: 10.1038/nrneph.2012.213. Epub 2012 Oct 2.
5
Autoimmune abnormalities of the alternative complement pathway in membranoproliferative glomerulonephritis and C3 glomerulopathy.补体替代途径自身免疫异常在膜增生性肾小球肾炎和 C3 肾小球病中的作用。
Pediatr Nephrol. 2019 Aug;34(8):1311-1323. doi: 10.1007/s00467-018-3989-0. Epub 2018 Jun 9.
6
Morphofunctional Effects of C5 Convertase Blockade in Immune Complex-Mediated Membranoproliferative Glomerulonephritis: Report of Two Cases with Evidence of Terminal Complement Activation.免疫复合物介导的膜增殖性肾小球肾炎中 C5 转化酶阻断的形态功能效应:伴有末端补体激活证据的两例报告。
Nephron. 2020;144(4):195-203. doi: 10.1159/000505403. Epub 2020 Feb 12.
7
Outcome of membranoproliferative glomerulonephritis and C3-glomerulopathy in children and adolescents.儿童和青少年膜增生性肾小球肾炎和 C3 肾小球病的结局。
Pediatr Nephrol. 2018 Dec;33(12):2289-2298. doi: 10.1007/s00467-018-4034-z. Epub 2018 Sep 20.
8
Treatment of C3 glomerulopathy with complement blockers.补体抑制剂治疗 C3 肾小球病。
Semin Thromb Hemost. 2014 Jun;40(4):472-7. doi: 10.1055/s-0034-1375299. Epub 2014 May 5.
9
Cluster Analysis Identifies Distinct Pathogenetic Patterns in C3 Glomerulopathies/Immune Complex-Mediated Membranoproliferative GN.聚类分析确定 C3 肾小球病/免疫复合物介导的膜增生性 GN 中的不同发病模式。
J Am Soc Nephrol. 2018 Jan;29(1):283-294. doi: 10.1681/ASN.2017030258. Epub 2017 Oct 13.
10
Hereditary and acquired complement dysregulation in membranoproliferative glomerulonephritis.膜增生性肾小球肾炎中的遗传性和获得性补体调节异常。
Thromb Haemost. 2009 Feb;101(2):271-8.

引用本文的文献

1
A case of C3 glomerulopathy with nephritis-associated plasmin receptor positivity without a history of streptococcal infection.一例 C3 肾小球病,伴有肾炎相关纤溶酶受体阳性,无链球菌感染史。
CEN Case Rep. 2022 May;11(2):259-264. doi: 10.1007/s13730-021-00662-2. Epub 2021 Nov 19.
2
Predictive factors for poor outcome in pediatric C3 glomerulonephritis.儿童C3肾小球肾炎预后不良的预测因素
Fukushima J Med Sci. 2018 Dec 8;64(3):142-150. doi: 10.5387/fms.2018-05. Epub 2018 Oct 27.
3
Recurrent postinfectious glomerulonephritis: an unusual evolution compatible with C3 glomerulopathy.
复发性感染后肾小球肾炎:一种与C3肾小球病相符的不寻常病程。
BMJ Case Rep. 2018 Feb 23;2018:bcr-2017-222979. doi: 10.1136/bcr-2017-222979.
4
The incidence of possible causes of membranoproliferative glomerulonephritis: a single-center experience.膜增生性肾小球肾炎可能病因的发生率:单中心经验
Hippokratia. 2015 Oct-Dec;19(4):314-8.
5
Differences in clinical findings, pathology, and outcomes between C3 glomerulonephritis and membranoproliferative glomerulonephritis.C3肾小球肾炎与膜增生性肾小球肾炎在临床表现、病理及预后方面的差异。
Pediatr Nephrol. 2016 Jul;31(7):1091-9. doi: 10.1007/s00467-015-3307-z. Epub 2016 Feb 4.
6
Timing of eculizumab therapy for C3 glomerulonephritis.依库珠单抗治疗C3肾小球肾炎的时机。
Clin Kidney J. 2015 Aug;8(4):449-52. doi: 10.1093/ckj/sfv065. Epub 2015 Jul 27.
7
Successful treatment of infectious endocarditis associated glomerulonephritis mimicking c3 glomerulonephritis in a case with no previous cardiac disease.成功治疗一例既往无心脏病史、酷似C3肾小球肾炎的感染性心内膜炎相关肾小球肾炎。
Case Rep Nephrol. 2014;2014:569047. doi: 10.1155/2014/569047. Epub 2014 Nov 23.
8
Eculizumab therapy in a patient with dense-deposit disease associated with partial lipodystropy.依库珠单抗治疗一名与部分脂肪营养不良相关的致密沉积物病患者。
Pediatr Nephrol. 2014 Jul;29(7):1283-7. doi: 10.1007/s00467-013-2748-5. Epub 2014 Jan 26.